These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16214409)

  • 1. Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy.
    Westermann D; Knollmann BC; Steendijk P; Rutschow S; Riad A; Pauschinger M; Potter JD; Schultheiss HP; Tschöpe C
    Eur J Heart Fail; 2006 Mar; 8(2):115-21. PubMed ID: 16214409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca2+-dependent action potential remodeling.
    Knollmann BC; Kirchhof P; Sirenko SG; Degen H; Greene AE; Schober T; Mackow JC; Fabritz L; Potter JD; Morad M
    Circ Res; 2003 Mar; 92(4):428-36. PubMed ID: 12600890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertrophy, fibrosis, and sudden cardiac death in response to pathological stimuli in mice with mutations in cardiac troponin T.
    Maass AH; Ikeda K; Oberdorf-Maass S; Maier SK; Leinwand LA
    Circulation; 2004 Oct; 110(15):2102-9. PubMed ID: 15466629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IMAGE CARDIO MED: Inducible malignant ventricular tachyarrhythmia in a patient with genotyped hypertrophic cardiomyopathy in absence of left ventricular hypertrophy or enlargement.
    Ariyarajah V; Tam JW; Khadem A
    Circulation; 2009 Jun; 119(21):e543-4. PubMed ID: 19487599
    [No Abstract]   [Full Text] [Related]  

  • 5. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model.
    Semsarian C; Ahmad I; Giewat M; Georgakopoulos D; Schmitt JP; McConnell BK; Reiken S; Mende U; Marks AR; Kass DA; Seidman CE; Seidman JG
    J Clin Invest; 2002 Apr; 109(8):1013-20. PubMed ID: 11956238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-type Ca2+ channel blockade prevents sudden death in mice with heart failure.
    Kinoshita H; Kuwahara K; Takano M; Arai Y; Kuwabara Y; Yasuno S; Nakagawa Y; Nakanishi M; Harada M; Fujiwara M; Murakami M; Ueshima K; Nakao K
    Circulation; 2009 Sep; 120(9):743-52. PubMed ID: 19687356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel troponin T mutation in familial dilated cardiomyopathy with gender-dependant severity.
    Stefanelli CB; Rosenthal A; Borisov AB; Ensing GJ; Russell MW
    Mol Genet Metab; 2004; 83(1-2):188-96. PubMed ID: 15464434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A contemporary approach to hypertrophic cardiomyopathy.
    Ho CY; Seidman CE
    Circulation; 2006 Jun; 113(24):e858-62. PubMed ID: 16785342
    [No Abstract]   [Full Text] [Related]  

  • 9. Advances in medical treatment of hypertrophic cardiomyopathy.
    Hamada M; Ikeda S; Shigematsu Y
    J Cardiol; 2014 Jul; 64(1):1-10. PubMed ID: 24735741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical and hemodynamic effects of diltiazem in patients with arterial hypertension associated with ischemic heart disease].
    Bychko MV
    Lik Sprava; 2007; (1-2):50-5. PubMed ID: 17682517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Calmodulin-Kinase II Activation Drives Disease Progression in Mutation-Specific Hypertrophic Cardiomyopathy.
    Lehman SJ; Tal-Grinspan L; Lynn ML; Strom J; Benitez GE; Anderson ME; Tardiff JC
    Circulation; 2019 Mar; 139(12):1517-1529. PubMed ID: 30586744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe heart failure and early mortality in a double-mutation mouse model of familial hypertrophic cardiomyopathy.
    Tsoutsman T; Kelly M; Ng DC; Tan JE; Tu E; Lam L; Bogoyevitch MA; Seidman CE; Seidman JG; Semsarian C
    Circulation; 2008 Apr; 117(14):1820-31. PubMed ID: 18362229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inotropic stimulation induces cardiac dysfunction in transgenic mice expressing a troponin T (I79N) mutation linked to familial hypertrophic cardiomyopathy.
    Knollmann BC; Blatt SA; Horton K; de Freitas F; Miller T; Bell M; Housmans PR; Weissman NJ; Morad M; Potter JD
    J Biol Chem; 2001 Mar; 276(13):10039-48. PubMed ID: 11113119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular insights from a novel cardiac troponin I mouse model of familial hypertrophic cardiomyopathy.
    Tsoutsman T; Chung J; Doolan A; Nguyen L; Williams IA; Tu E; Lam L; Bailey CG; Rasko JE; Allen DG; Semsarian C
    J Mol Cell Cardiol; 2006 Oct; 41(4):623-32. PubMed ID: 16950368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent FHC-related cardiac troponin T mutations exhibit specific alterations in myocellular contractility and calcium kinetics.
    Haim TE; Dowell C; Diamanti T; Scheuer J; Tardiff JC
    J Mol Cell Cardiol; 2007 Jun; 42(6):1098-110. PubMed ID: 17490679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of diltiazem on lipid profiles and heart rate in hypertensive patients].
    Carré A; Joire JE; Mounier-Vehier C; Lequeuche B
    Ann Cardiol Angeiol (Paris); 1999 Mar; 48(3):221-6. PubMed ID: 12555384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A polymorphic modifier gene alters the hypertrophic response in a murine model of familial hypertrophic cardiomyopathy.
    Semsarian C; Healey MJ; Fatkin D; Giewat M; Duffy C; Seidman CE; Seidman JG
    J Mol Cell Cardiol; 2001 Nov; 33(11):2055-60. PubMed ID: 11708849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Calcium antagonists in cardiomyopathy].
    Takabatake Y
    Nihon Rinsho; 1991 Jan; 49(1):168-75. PubMed ID: 2002597
    [No Abstract]   [Full Text] [Related]  

  • 19. Dilated cardiomyopathy mutant tropomyosin mice develop cardiac dysfunction with significantly decreased fractional shortening and myofilament calcium sensitivity.
    Rajan S; Ahmed RP; Jagatheesan G; Petrashevskaya N; Boivin GP; Urboniene D; Arteaga GM; Wolska BM; Solaro RJ; Liggett SB; Wieczorek DF
    Circ Res; 2007 Jul; 101(2):205-14. PubMed ID: 17556658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite marker analysis in the treatment and diagnosis of familial hypertrophic cardiomyopathy.
    Smolik S; Domal-Kwiatkowska D; Kapral M; Weglarz L
    Acta Pol Pharm; 2010; 67(6):669-72. PubMed ID: 21229884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.